AI assistant
Nuvectis Pharma, Inc. — Director's Dealing 2022
Aug 30, 2022
33912_dirs_2022-08-30_6254cb13-4e26-449c-9d8a-67ceaff34582.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-08-23
Reporting Person: BENTSUR RON (Director, Chairman & CEO, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-23 | Common Stock | P | 500 | $9.00 | Acquired | 3007909 | Direct |
| 2022-08-29 | Common Stock | P | 1000 | $9.07 | Acquired | 3008909 | Direct |
Footnotes
F1: Includes 96,759 shares of restricted stock and 120,000 restricted stock units.
F2: Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.99 to $9.31. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.